Literature DB >> 16631679

Prevalence of benign disease in patients undergoing resection for suspected lung cancer.

Michael A Smith1, Richard J Battafarano, Bryan F Meyers, Jennifer Bell Zoole, Joel D Cooper, G Alexander Patterson.   

Abstract

BACKGROUND: In this era of expanded lung cancer screening, accurate differentiation of benign from malignant lesions remains an important problem. We sought to characterize our experience with focal pulmonary lesions suggestive of lung cancer and subsequently proven benign on surgical resection.
METHODS: A retrospective analysis was performed on 1,560 patients who underwent resection for focal pulmonary lesions at our institution from January 1995 to December 2002. Computed tomography and pathology reports were reviewed for all patients. Fluorine-18-fluorodeoxyglucose positron emission tomography studies were performed on 43 patients.
RESULTS: Benign processes were found on pathologic examination in 140 patients (9%). Resection was accomplished by thoracotomy in 103 patients (74%), video-assisted thoracoscopy in 36 patients (26%), and sternotomy in 1 patient (0.7%). Seventy patients (50%) underwent mediastinoscopy before resection. There was 1 (0.7%) perioperative death. Pathologic diagnoses from the pulmonary resections revealed granulomatous inflammation in 91 patients (65%), hamartoma in 17 patients (12%), pneumonia or pneumonitis in 14 patients (10%), fibrosis in 5 patients (4%), and other in 13 patients (9%). Fluorine-18-fluorodeoxyglucose positron emission tomography imaging suggested malignancy in 22 of 43 patients and benign lesion in 20 of 43 patients (1 study was not interpretable). Thirty-eight patients underwent needle biopsy before surgery. Of these, 29 samples were nondiagnostic, 5 samples were negative, and 4 samples were considered positive for malignancy.
CONCLUSIONS: Despite thorough clinical assessment, advanced imaging technology, and needle biopsy, many patients continue to undergo surgery for benign disease. Aggressive attempts to diagnose and treat early stage lung cancer must be tempered with this understanding.

Entities:  

Mesh:

Year:  2006        PMID: 16631679     DOI: 10.1016/j.athoracsur.2005.11.010

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  30 in total

1.  Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules.

Authors:  Chad V Pecot; Ming Li; Xueqiong J Zhang; Rama Rajanbabu; Ciara Calitri; Aaron Bungum; James R Jett; Joe B Putnam; Carol Callaway-Lane; Steve Deppen; Eric L Grogan; David P Carbone; John A Worrell; Karel G M Moons; Yu Shyr; Pierre P Massion
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-28       Impact factor: 4.254

2.  Calcified granulomatous disease: occupational associations and lack of familial aggregation.

Authors:  Robert M Reed; Anthony Amoroso; Salman Hashmi; Seth Kligerman; Alan R Shuldiner; Braxton D Mitchell; Giora Netzer
Journal:  Lung       Date:  2014-07-20       Impact factor: 2.584

3.  Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503.

Authors:  Leslie J Kohman; Lin Gu; Nasser Altorki; Ernest Scalzetti; Linda J Veit; Jason M Wallen; Xiaofei Wang
Journal:  J Thorac Cardiovasc Surg       Date:  2017-02-07       Impact factor: 5.209

4.  Thoracic operations for pulmonary nodules are frequently not futile in patients with benign disease.

Authors:  Eric L Grogan; Jodi J Weinstein; Stephen A Deppen; Joe B Putnam; Jonathan C Nesbitt; Eric S Lambright; Ronald C Walker; Robert S Dittus; Pierre P Massion
Journal:  J Thorac Oncol       Date:  2011-10       Impact factor: 15.609

5.  Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation.

Authors:  James M Isbell; Stephen Deppen; Joe B Putnam; Jonathan C Nesbitt; Eric S Lambright; Aaron Dawes; Pierre P Massion; Theodore Speroff; David R Jones; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2011-01       Impact factor: 4.330

6.  Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions.

Authors:  Yin P Hung; Gary M Hunninghake; Ezra R Miller; Rachel Putman; Mizuki Nishino; Tetsuro Araki; Hiroto Hatabu; Lynette M Sholl; Marina Vivero
Journal:  Hum Pathol       Date:  2019-01-15       Impact factor: 3.466

7.  Factors that influence physician decision making for indeterminate pulmonary nodules.

Authors:  Anil Vachani; Nichole T Tanner; Jyoti Aggarwal; Charles Mathews; Paul Kearney; Kenneth C Fang; Gerard Silvestri; Gregory B Diette
Journal:  Ann Am Thorac Soc       Date:  2014-12

8.  Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses.

Authors:  S P Georgiadou; F L Sampsonas; D Rice; J M Granger; S Swisher; D P Kontoyiannis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-16       Impact factor: 3.267

9.  Pulmonary chondromatous hamartoma with pleural dissemination: report of a case.

Authors:  Kazuhiro Sakamoto; Kohei Ando; Daisuke Noma
Journal:  Surg Today       Date:  2014-08-07       Impact factor: 2.549

10.  Predicting lung cancer prior to surgical resection in patients with lung nodules.

Authors:  Stephen A Deppen; Jeffrey D Blume; Melinda C Aldrich; Sarah A Fletcher; Pierre P Massion; Ronald C Walker; Heidi C Chen; Theodore Speroff; Catherine A Degesys; Rhonda Pinkerman; Eric S Lambright; Jonathan C Nesbitt; Joe B Putnam; Eric L Grogan
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.